

Patrizia Querzoli

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8557186/publications.pdf>

Version: 2024-02-01

45
papers

5,429
citations

279798
23
h-index

254184
43
g-index

46
all docs

46
docs citations

46
times ranked

8188
citing authors

#	ARTICLE	IF	CITATIONS
1	MicroRNA Gene Expression Deregulation in Human Breast Cancer. Cancer Research, 2005, 65, 7065-7070.	0.9	3,719
2	Oncogenic Role of <i>miR-483-3p</i> at the <i>IGF2/483</i> Locus. Cancer Research, 2010, 70, 3140-3149.	0.9	272
3	Trop-2 Is a Determinant of Breast Cancer Survival. PLoS ONE, 2014, 9, e96993.	2.5	131
4	MicroRNA profiling for the identification of cancers with unknown primary tissue of origin. Journal of Pathology, 2011, 225, 43-53.	4.5	117
5	An original approach in the diagnosis of early breast cancer: use of the same radiopharmaceutical for both non-palpable lesions and sentinel node localisation. European Journal of Nuclear Medicine and Molecular Imaging, 2001, 28, 1589-1596.	2.1	89
6	Epidermal growth factor receptor in human breast cancer: Correlation with steroid hormone receptors and axillary lymph node involvement. European Journal of Cancer & Clinical Oncology, 1988, 24, 1685-1690.	0.7	82
7	Diagnostic and prognostic microRNAs in the serum of breast cancer patients measured by droplet digital PCR. Biomarker Research, 2015, 3, 12.	6.8	80
8	miR-125b targets erythropoietin and its receptor and their expression correlates with metastatic potential and ERBB2/HER2 expression. Molecular Cancer, 2013, 12, 130.	19.2	73
9	Axillary Lymph Node Nanometastases Are Prognostic Factors for Disease-Free Survival and Metastatic Relapse in Breast Cancer Patients. Clinical Cancer Research, 2006, 12, 6696-6701.	7.0	71
10	Phospholipase C- β 2 promotes mitosis and migration of human breast cancer-derived cells. Carcinogenesis, 2007, 28, 1638-1645.	2.8	62
11	p53 Status Identifies Two Subgroups of Triple-negative Breast Cancers with Distinct Biological Features. Japanese Journal of Clinical Oncology, 2011, 41, 172-179.	1.3	59
12	Loss of methylation at chromosome 11p15.5 is common in human adult tumors. Oncogene, 2002, 21, 2564-2572.	5.9	52
13	Clinical and Therapeutic Importance of Sentinel Node Biopsy of the Internal Mammary Chain in Patients with Breast Cancer: A Single-Center Study with Long-Term Follow-Up. Annals of Surgical Oncology, 2006, 13, 1338-1343.	1.5	50
14	Molecular Subtyping of Breast Cancer from Traditional Tumor Marker Profiles Using Parallel Clustering Methods. Clinical Cancer Research, 2006, 12, 781-790.	7.0	41
15	High expression of 90K (Mac-2 BP) is associated with poor survival in node-negative breast cancer patients not receiving adjuvant systemic therapies. International Journal of Cancer, 2009, 124, 333-338.	5.1	36
16	Biological Profile of in Situ Breast Cancer Investigated by Immunohistochemical Technique. Cancer Detection and Prevention, 1998, 22, 313-318.	2.1	36
17	Polycystin-1 regulates amphiregulin expression through CREB and AP1 signalling: implications in ADPKD cell proliferation. Journal of Molecular Medicine, 2012, 90, 1267-1282.	3.9	34
18	Commentary on human mammary preneoplasia. The estrogen receptor-promotion hypothesis. The Journal of Steroid Biochemistry, 1988, 30, 105-106.	1.1	32

#	ARTICLE	IF	CITATIONS
19	Pre-operative management of Pleomorphic and florid lobular carcinoma in situ of the breast: Report of a large multi-institutional series and review of the literature. <i>European Journal of Surgical Oncology</i> , 2019, 45, 2279-2286.	1.0	32
20	MicroRNAs: Toward the Clinic for Breast Cancer Patients. <i>Seminars in Oncology</i> , 2011, 38, 764-775.	2.2	30
21	90K (Mac-2 BP) gene expression in breast cancer and evidence for the production of 90K by peripheral-blood mononuclear cells. , 1998, 79, 23-26.		29
22	Biophenotypes and survival of BRCA1 and TP53 deleted breast cancer in young women. <i>Breast Cancer Research and Treatment</i> , 2001, 66, 135-142.	2.5	27
23	Sex hormone receptor levels in laryngeal carcinoma: a comparison between protein and RNA evaluations. <i>European Archives of Oto-Rhino-Laryngology</i> , 2008, 265, 1089-1094.	1.6	24
24	Trop-2 induces ADAM10-mediated cleavage of E-cadherin and drives EMT-less metastasis in colon cancer. <i>Neoplasia</i> , 2021, 23, 898-911.	5.3	24
25	Expression of p21ras gene products in breast cancer relates to histological types and to receptor and nodal status. <i>Breast Cancer Research and Treatment</i> , 1988, 12, 23-30.	2.5	23
26	Increased overall survival independent of RECIST response in metastatic breast cancer patients continuing trastuzumab treatment: evidence from a retrospective study. <i>Breast Cancer Research and Treatment</i> , 2011, 128, 147-154.	2.5	23
27	Modulation of biomarkers in minimal breast carcinoma. , 1998, 83, 89-97.		22
28	Application of quantitative analysis to biologic profile evaluation in breast cancer. <i>Cancer</i> , 1995, 76, 2510-2517.	4.1	21
29	Decreased heme-oxygenase (HO)-1 in the macrophages of non-small cell lung cancer. <i>Lung Cancer</i> , 2008, 59, 192-197.	2.0	19
30	High-sensitivity assay for monitoring ESR1 mutations in circulating cell-free DNA of breast cancer patients receiving endocrine therapy. <i>Scientific Reports</i> , 2018, 8, 4371.	3.3	14
31	Serologic investigation of undifferentiated nasopharyngeal carcinoma and simian virus 40 infection. <i>Head and Neck</i> , 2016, 38, 232-236.	2.0	13
32	Breast Cancer and Simian Virus 40 Infection. <i>Epidemiology</i> , 2013, 24, 464-465.	2.7	12
33	GATA3 as an Adjunct Prognostic Factor in Breast Cancer Patients with Less Aggressive Disease: A Study with a Review of the Literature. <i>Diagnostics</i> , 2021, 11, 604.	2.6	12
34	An international study comparing conventional versus mRNA level testing (TargetPrint) for ER, PR, and HER2 status of breast cancer. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2016, 469, 297-304.	2.8	11
35	Immunohistochemical Expression of c-erbB-2 in Human Breast Cancer by Monoclonal Antibody: Correlation with Lymph Node and Er Status. <i>Tumori</i> , 1990, 76, 461-464.	1.1	10
36	Clinical Usefulness of Estrogen Receptor Immunocytochemistry in Human Breast Cancer. <i>Tumori</i> , 1992, 78, 287-290.	1.1	10

#	ARTICLE	IF	CITATIONS
37	Cytoplasmic Trop-1/Ep-CAM Overexpression is Associated with a Favorable Outcome in Node-positive Breast Cancer. Japanese Journal of Clinical Oncology, 2012, 42, 1128-1137.	1.3	9
38	Human herpesvirus 7 is latent in gastric mucosa. Journal of Medical Virology, 2001, 63, 277-283.	5.0	6
39	Biological Heterogeneity of Breast Carcinoma in Situ. Annals of the New York Academy of Sciences, 1996, 784, 458-461.	3.8	4
40	Sentinel Node and Bone Marrow Micrometastases and Nanometastases. Current Breast Cancer Reports, 2010, 2, 96-106.	1.0	4
41	Treatment of a relapsing facial pyoderma gangrenosum (malignant pyoderma). International Journal of Dermatology, 2013, 52, 753-756.	1.0	4
42	Lymph Node Micrometastases Do Influence Breast Cancer Outcome. Journal of Clinical Oncology, 2015, 33, 3977-3978.	1.6	4
43	Microscopic tumor foci in axillary lymph nodes may reveal the recurrence dynamics of breast cancer. Cancer Communications, 2019, 39, 1-4.	9.2	4
44	Biological Staging of Incipient, in Situ, and Invasive Breast Carcinomas. Annals of the New York Academy of Sciences, 1996, 784, 381-394.	3.8	1
45	EpCAM Expression Is an Indicator of Increased Incidence of Relapse in p53-Positive Breast Cancer. Cancer and Clinical Oncology, 2012, 2, .	0.2	0